Literature DB >> 11140777

Selective serotonin re-uptake inhibitors for children and adolescents.

C F Ziervogel1.   

Abstract

OBJECTIVES: 1) To briefly review the scientific basis for the use of selective serotonin re-uptake inhibitors (SSRIs) in children and adolescents. 2) To review the current data on the efficacy, safety and tolerability in children and adolescents.
METHOD: A Medline search back to 1990 was conducted. Review articles and double blind, placebo controlled trials were critically reviewed. Additional hand searches were performed with key journals and in specific areas of interest for this paper.
RESULTS: Most of the published papers are from North America. There is an increasing use of SSRIs in child and adolescent psychiatry. The main disorders studied are mood and anxiety disorders. The data supporting efficacy is still limited. The most robust data is in the treatment of OCD and depression.
CONCLUSION: Taking the limited data together with clinical experience and with adult studies, there is a valuable role for SSRIs as a component of treatment for various child and adolescent psychiatric disorders.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11140777     DOI: 10.1007/s007870070016

Source DB:  PubMed          Journal:  Eur Child Adolesc Psychiatry        ISSN: 1018-8827            Impact factor:   4.785


  24 in total

Review 1.  The new antidepressants. Selective serotonin reuptake inhibitors.

Authors:  M J Labellarte; J T Walkup; M A Riddle
Journal:  Pediatr Clin North Am       Date:  1998-10       Impact factor: 3.278

Review 2.  Pharmacology of the selective serotonin reuptake inhibitors in children and adolescents.

Authors:  H L Leonard; J March; K C Rickler; A J Allen
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1997-06       Impact factor: 8.829

3.  Child and adolescent obsessive-compulsive disorder treated with citalopram: findings from an open trial of 23 cases.

Authors:  P H Thomsen
Journal:  J Child Adolesc Psychopharmacol       Date:  1997       Impact factor: 2.576

4.  A clinical psychotherapy trial for adolescent depression comparing cognitive, family, and supportive therapy.

Authors:  D A Brent; D Holder; D Kolko; B Birmaher; M Baugher; C Roth; S Iyengar; B A Johnson
Journal:  Arch Gen Psychiatry       Date:  1997-09

5.  Controlled trial of a brief cognitive-behavioural intervention in adolescent patients with depressive disorders.

Authors:  A Wood; R Harrington; A Moore
Journal:  J Child Psychol Psychiatry       Date:  1996-09       Impact factor: 8.982

6.  Fluoxetine for childhood anxiety disorders.

Authors:  B Birmaher; G S Waterman; N Ryan; M Cully; L Balach; J Ingram; M Brodsky
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1994-09       Impact factor: 8.829

7.  Treatment of elective mutism with fluoxetine: a double-blind, placebo-controlled study.

Authors:  B Black; T W Uhde
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1994-09       Impact factor: 8.829

Review 8.  Pharmacologic treatment for children and adolescents with anxiety disorders.

Authors:  B Birmaher; A K Yelovich; J Renaud
Journal:  Pediatr Clin North Am       Date:  1998-10       Impact factor: 3.278

9.  Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial.

Authors:  J S March; J Biederman; R Wolkow; A Safferman; J Mardekian; E H Cook; N R Cutler; R Dominguez; J Ferguson; B Muller; R Riesenberg; M Rosenthal; F R Sallee; K D Wagner; H Steiner
Journal:  JAMA       Date:  1998-11-25       Impact factor: 56.272

10.  A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression.

Authors:  G J Emslie; A J Rush; W A Weinberg; R A Kowatch; C W Hughes; T Carmody; J Rintelmann
Journal:  Arch Gen Psychiatry       Date:  1997-11
View more
  1 in total

1.  Efficacy of antidepressants in child and adolescent depression: a meta-analytic study.

Authors:  K Papanikolaou; C Richardson; A Pehlivanidis; Z Papadopoulou-Daifoti
Journal:  J Neural Transm (Vienna)       Date:  2005-08-03       Impact factor: 3.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.